Gagnon Robert E. 4

What Happened Robert E. Gagnon, a director of Harvard Bioscience, was granted 16,556 restricted stock units (RSUs) on June 9, 2026. The award was reported at $0.00 per share (total reported value $0), reflecting a compensation grant rather than a market purchase or sale. The RSUs will convert to common shares only when they vest.

Key Details

• Transaction date: 2026-06-09; Form 4 filed 2026-06-11 (within the typical two-business-day reporting window).
• Transaction type/code: A (award/grant); 16,556 RSUs granted at $0.00.
• Shares owned after transaction: 27,556 beneficially owned (16,556 RSUs + 11,000 existing common shares), per the filing.
• Vesting: Award vests in full either immediately prior to the company’s next annual meeting or one year from the grant date, whichever is earlier (Footnote 1).
• Reverse split: A 10-for-1 reverse stock split on March 13, 2026 adjusted prior figures; the 11,000 existing shares were previously reported as 110,000 RSUs now vested (Footnote 3).
• Nature of transaction: Compensation award (not a purchase or sale), so it’s standard director pay rather than an open-market signal.

Context RSUs are restricted until they vest, so this grant increases Gagnon’s potential future stake if vesting conditions are met but is not an immediate acquisition of tradable shares. Such grants are common for director compensation and do not necessarily indicate the insider is buying or selling based on near-term views of the stock.